Noradox (Doxazosin Mesilate)

Doxazosin mesilate, the active ingredient in Noradox, is an alpha-1 adrenergic blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension and for relief of lower urinary tract symptoms associated with benign prostatic hyperplasia in adult patients.

GNH USA supplies Noradox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Doxazosin mesilate acts on the alpha‑1 adrenergic receptor pathway to lower blood pressure and relax prostatic smooth muscle.

- Hypertension: reduces systemic vascular resistance, helping to achieve target blood pressure levels. - Benign prostatic hyperplasia (BPH): eases urinary obstruction by decreasing smooth‑muscle tone in the prostate and bladder neck. - Lower urinary tract symptoms (LUTS) associated with BPH: improves urinary flow and reduces urgency and frequency.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue or tiredness. - Nasal congestion. - Swelling of the ankles or feet. - Nausea.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Heart failure exacerbation. - Liver enzyme elevations. - Priapism. - Allergic reactions such as rash, itching, or angioedema. - Persistent erectile dysfunction.

Before initiating therapy, consider patient‑specific factors and monitor for potential risks.

- Cardiovascular status: assess for orthostatic hypotension, especially in the elderly. - Renal or hepatic impairment: dose adjustment may be required. - Concomitant antihypertensives: monitor for additive blood‑pressure lowering effects. - History of priapism: avoid use due to risk of recurrence. - Pregnancy and lactation: safety not established; use only if clearly needed. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Doxazosin mesilate may interact with several drug classes; clinical monitoring is advised.

Major Interactions (Avoid):\n- Phosphodiesterase‑5 inhibitors (e.g., sildenafil): can cause profound hypotension. - Other alpha‑blockers: additive vasodilatory effect may lead to severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may increase risk of orthostatic hypotension. - Antihypertensive agents (ACE inhibitors, ARBs, beta‑blockers): may require dose adjustments. - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma levels of doxazosin.